Privacy, Disclaimer & General Conditions

News Argo advised Fund+ NV on the divestment of its shares in Ogeda NV to Astellas Pharma Inc.
3 April 2017

Argo advised Fund+ NV, an investment fund with a focus on the bio-tech industry, on the divestment of its shareholding in Ogeda NV, a Belgian bio-tech clinical-stage drug discovery company that discovers and develops small molecule drugs targeting G-protein coupled receptors, to Astellas Pharma Inc, a Japanese pharmaceutical listed company with a focus on urology, oncology, immunology, nephrology and neuroscience.

The aggregate transaction value amounts to approximately EUR 800 million.

Back to news
Stay in the loop.